Literature DB >> 16270607

Clinical strategy in hereditary hemorrhagic telangiectasia.

Thomas S Kühnel1, Birgit H Wagner, Christian P Schurr, Jürgen Strutz.   

Abstract

BACKGROUND: Hereditary hemorrhagic telangiectasia (HHT) is a recurrent bleeding tendency caused by vascular malformations and preferentially involving the mucous membrane of the nose. The rhinological management of epistaxis is a challenge in which the frequency of bleeding has to be reduced without damage to the nasal mucosa, despite the fact that therapy necessarily has to be repeated.
METHODS: The clinical course in 30 patients with HHT was monitored prospectively. Nasal mucosal efflorescences underwent Nd:YAG laser therapy at individually defined intervals, and the effect on the frequency and duration of bleeding was documented, as were adverse effects.
RESULTS: No serious adverse effects (e.g., septal defects or synechiae) were observed as a consequence of therapy. During the course of laser therapy and ongoing compliance with nasal mucosal care instructions, the frequency of bleeding fell from "several times daily" to "every 2 weeks."
CONCLUSION: In conjunction with Nd:YAG laser therapy, ongoing and consistent care of the nasal mucosa is a proven and effective treatment regimen in HHT. As an integral element in an interdisciplinary strategy for diagnosis and therapy, this regimen yields satisfactory quality of life while avoiding local complications.

Entities:  

Mesh:

Year:  2005        PMID: 16270607

Source DB:  PubMed          Journal:  Am J Rhinol        ISSN: 1050-6586


  8 in total

1.  Influence of temporary nasal occlusion (tNO) on epistaxis frequency in patients with hereditary hemorrhagic telangiectasia (HHT).

Authors:  Kornelia E C Wirsching; Frank Haubner; Thomas S Kühnel
Journal:  Eur Arch Otorhinolaryngol       Date:  2017-01-09       Impact factor: 2.503

Review 2.  Connective tissue disorders and cardiovascular complications: the indomitable role of transforming growth factor-beta signaling.

Authors:  Jason B Wheeler; John S Ikonomidis; Jeffrey A Jones
Journal:  Adv Exp Med Biol       Date:  2014       Impact factor: 2.622

3.  Efficiency of laser treatment in patients with hereditary hemorrhagic telangiectasia.

Authors:  Gita Jørgensen; Bibi Lange; Jens Højberg Wanscher; Anette Drøhse Kjeldsen
Journal:  Eur Arch Otorhinolaryngol       Date:  2011-06-26       Impact factor: 2.503

4.  [Bevacizumab in therapy-refractory epistaxis: case report of low-dose antibody therapy for hereditary hemorrhagic telangiectasia].

Authors:  C Rohrmeier; T S Kühnel
Journal:  HNO       Date:  2012-11       Impact factor: 1.284

5.  A retrospective analysis of low dose, intranasal injected bevacizumab (Avastin) in hereditary haemorrhagic telangiectasia.

Authors:  C Rohrmeier; H G Sachs; T S Kuehnel
Journal:  Eur Arch Otorhinolaryngol       Date:  2011-07-31       Impact factor: 2.503

6.  Diode laser in the treatment of epistaxis in patients with hereditary haemorrhagic telangiectasia.

Authors:  M L Fiorella; L Lillo; R Fiorella
Journal:  Acta Otorhinolaryngol Ital       Date:  2012-06       Impact factor: 2.124

7.  Nasal surgery in patients with systemic disorders.

Authors:  Florian Sachse; Wolfgang Stoll
Journal:  GMS Curr Top Otorhinolaryngol Head Neck Surg       Date:  2011-04-27

8.  Update on Clinical Strategies in Hereditary Hemorrhagic Telangiectasia from an ENT Point of View.

Authors:  Kornelia E C Wirsching; Thomas S Kühnel
Journal:  Clin Exp Otorhinolaryngol       Date:  2016-07-21       Impact factor: 3.372

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.